Online citations, reference lists, and bibliographies.
← Back to Search

S3 – Guidelines On The Treatment Of Psoriasis Vulgaris Update 2011

A. Nast, W. Boehncke, U. Mrowietz, H. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, A. Sammain, M. Schlaeger, M. Sebastian, W. Sterry, V. Streit, M. Augustin, R. Erdmann, J. Klaus, J. Koza, Siegrid Müller, H. Orzechowski, S. Rosumeck, G. Schmid-Ott, T. Weberschock, B. Rzany
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Alexander Nast, Wolf-Henning Boehncke, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Adel Sammain, Martin Schlaeger, Michael Sebastian, Wolfram Sterry, Volker Streit, Matthias Augustin, Ricardo Erdmann, Joachim Klaus, Joachim Koza, Siegrid Müller, Hans-Dieter Orzechowski, Stefanie Rosumeck, Gerhard Schmid-Ott, Tobias Weberschock, Berthold Rzany (1) Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Vene-rologie und Allergologie, Charité – Universitätsmedizin Berlin, Germany (2) Zentrum der Dermatologie und Venerologie, Klinikum der Johann Wolfgang Goethe Universität, Frankfurt/Main, Germany (3) Klinik für Dermatologie, Venerologie, Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Germany (4) Hautu. Allergieklinik, Klinikum Hanau, Germany (5) Psoriasisstudienzentrum, Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Germany (6) Dermatologikum Hamburg, Germany (7) Dermatologist in private practice, Osnabrück, Germany (8) Dermatologist in private practice, Oldenburg, Germany (9) Dermatologist in private practice, Mahlow, Germany (10) Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Germany (11) Niedergelassener Dermatologe, Buchholz, Germany (12) Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Dermatologie und Venerologie, Hamburg, Germany (13) Deutscher Psoriasis Bund e.V., Germany (14) Nursing care representative, Ravenstein, Germany (15) Institut für Klinische Pharmakologie und Toxikologie, Charité – Universitätsmedizin Berlin, Germany (16) Berolina Klinik, Löhne, Germany
This paper references
10.1001/archderm.1996.03890280081011
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group.
(1996)
A randomized comparison of three conventional modes of treatment of psoriasis of the scalp.
S. Ross (1981)
10.1080/09546630410023322
A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
H. Torras (2004)
10.1111/1523-1747.EP12512282
The effect of anthralin and its derivatives on epidermal cell kinetics.
L. B. Fisher (1975)
10.1046/j.1365-2230.2001.00828.x
Phototherapy for psoriasis
H. Hoenigsmann (1982)
10.1046/j.1365-4362.2000.00913.x
Psoralen–ultraviolet A therapy vs. psoralen–ultraviolet B therapy in the treatment of plaque‐type psoriasis: our experience with Fitzpatrick skin type IV
K. Khurshid (2000)
10.1111/j.1365-2133.2006.07561.x
A double‐blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation
John E M Körver (2007)
10.1159/000248398
Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
P. Berbis (1989)
10.2340/0001555576353356
Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis.
I. Hagemann (1996)
10.1016/0190-9622(95)90189-2
Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
G. Mahrle (1995)
10.1067/MJD.2002.125075
Medium-dose 308-nm excimer laser for the treatment of psoriasis.
M. Trehan (2002)
10.1111/j.1365-2249.1994.tb06244.x
Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions
P. Ettehadi (1994)
10.1001/ARCHDERM.1979.04010070016013
Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation.
P. Frost (1979)
10.1016/S0190-9622(94)70138-5
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.
R. M. Grossman (1994)
10.1002/14651858.CD000951.pub2
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
B. Shea (2013)
10.1111/j.1600-0781.2006.00249.x
8‐methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis
N. Amornpinyokeit (2006)
10.1177/1721727X0500300108
Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients
G. Vena (2005)
10.1111/j.1610-0387.2005.05729.x
Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany
K. Berger (2005)
10.1111/j.1610-0387.2007.06240.x
Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study
O. Schöffski (2007)
10.1016/J.JACI.2004.03.021
Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
E. Schuller (2004)
10.1111/j.1600-0625.1992.tb00071.x
A reappraisal of the use of 5‐methoxypsoralen in the therapy of psoriasis
P. Calzavara-Pinton (1992)
10.1159/000017515
Depth Psychology-Founded Psychotherapy of Psoriatic Patients – Treatment of a Patient with Chronic Recidivating Psoriasis vulgaris
G. Schmid‐Ott (2000)
10.2340/00015555733740
Down-regulation of epidermal growth factor receptors by dithranol.
L. Kemény (1993)
10.1016/j.jaad.2009.07.022
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
A. Menter (2010)
10.1046/j.1365-2133.1998.02124.x
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study
Mrowietz (1998)
10.1002/ART.20335
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
P. Mease (2004)
10.1111/j.1468-3083.1997.tb00509.x
Dead sea bath salt for the treatment of psoriasis vulgaris: a double‐blind controlled study
S. Halevy (1997)
10.1007/S10227-001-0006-0
Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis
L. Stein (2001)
10.1016/S0140-6736(08)60726-6
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
K. Papp (2008)
10.1016/J.JAAD.2006.05.026
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.
J. Koo (2006)
10.1136/ard.2007.070771
Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis
J. Augustsson (2007)
10.1111/j.1365-2133.2006.07141.x
Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study
A. Erceg (2006)
10.1159/000066425
Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis
D. Thąci (2002)
10.2340/0001555574295297
The systemic effect of dithranol treatment in psoriasis.
M. Goodfield (1994)
10.1046/j.1365-2133.1999.140S54018.x
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis
Gollnick (1999)
10.2340/00015555-0216
Cutaneous vascular alterations in psoriatic patients treated with cyclosporine.
G. Stinco (2007)
10.1046/J.1439-0353.2003.03615.X
Recommendations for phototherapy and photochemotherapy
E. Hölzle (2003)
10.1016/S0140-6736(88)91335-9
INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS
A. Powles (1988)
10.1067/MJD.2003.169
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
A. Freeman (2003)
10.3945/AJCN.2008.26427
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
P. Gisondi (2008)
10.1080/09546630701499291
Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate‐to‐severe chronic plaque psoriasis: A comparative study
N. Ranjan (2007)
The impact of the frequency of short contact dithranol treatment.
M. Prins (2001)
10.1016/S0091-6749(96)70163-X
Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells.
W. Sperr (1996)
Liver biopsy in methotrexate-treated psoriatics-a re-evalution.
H. Zachariae (1975)
10.1111/j.1365-2133.2003.05653.x
Optimizing the frequency of outpatient short‐contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within‐patient controlled trial
S. R. McBride (2003)
10.1001/ARCHDERM.1967.01600310008002
Methotrexate for psoriasis.
R. Rees (1967)
10.1111/j.1365-2133.1987.tb04920.x
Dithranol mediates pro‐oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation
R. Anderson (1987)
10.2340/00015555-0340
Outcome of "short-term" Dead Sea climatotherapy for psoriasis.
A. Cohen (2008)
10.1111/j.1365-2133.1989.tb01406.x
A double‐blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
J. Lauharanta (1989)
Salicylsäure zur topischen Anwendung. Bundesanzeiger. 19.06.1990, Korrektur 20.09.1990 (korrigierte Fassung in ZrvA Dez
Anonymous (1990)
10.1046/j.1468-3083.2003.00519_12.x
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin
K. Agnew (2003)
10.1007/BF01105083
Cyclosporin A, FK506 and dithranol alter tyrosine-specific protein phosphorylation in HaCaT keratinocytes
H. M. Ockenfels (2005)
10.1159/000248567
Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.
J. Saurat (1988)
10.1111/j.1600-0781.2008.00371.x
Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study
R. Youssef (2008)
Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis
A. Frappaz (1993)
10.1001/ARCHDERM.141.1.43
Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment.
C. Carroll (2005)
10.1684/EJD.2008.0311
The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions.
Jana Trott (2008)
Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A
J. Nakayama (1996)
10.1016/J.JAAD.2006.01.004
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study.
P. Asawanonda (2006)
LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.
J. Bagel (2009)
Verlag GmbH 368. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 longterm methotrexate-treated psoriatics. A preliminary study
© Psoriasis-Leitliniengruppe Der (1983)
10.1684/ejd.2010.0815
Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.
I. Schaefer (2010)
10.1001/ARCHDERM.142.7.836
Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.
S. S. Yones (2006)
10.1136/ARD.2004.032268
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C. Antoni (2005)
Optimization of narrow-band uvb with a 5% oleic acid cream in the treatment of psoriasis.
G. Martín-Ezquerra (2007)
Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis.
A. Mussi (1997)
10.1055/s-0029-1214673
[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
R. Diel (2009)
The Hospital Anxiety and Depression Scale.
G. Huston (1987)
10.1016/J.JAAD.2007.09.010
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
A. Menter (2008)
Richtlijn foto(chemo)therapie en systemische therapie bij ernstige chronische plaque psoriasis
(2003)
10.2165/00044011-200626040-00008
Treatment of Psoriasis Vulgaris with the Two-Compound Product Calcipotriol/Betamethasone Dipropionate followed by Different Formulations of Calcipotriol
N. Cassano (2006)
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
L. Kircik (2008)
A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
J. Koo (1998)
Fachinformation essex pharma. aktuelle Version
10.1111/j.1468-3083.2007.02152.x
A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis
T. Brockow (2007)
10.1159/000249793
Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.
A. Nyfors (1983)
Verlag GmbH fair-skinned individuals with psoriasis
© Psoriasis-Leitliniengruppe Der (1999)
10.1016/S0190-9622(82)70157-4
Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis.
B. Paul (1982)
Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.
A. Nyfors (1978)
10.1007/s004030050251
Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis?
K. Asadullah (1997)
[Peroral long-term treatment of psoriasis using fumaric acid derivatives].
W. Bayard (1987)
10.1111/j.1365-2133.1990.tb04192.x
Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis
A. Finlay (1990)
10.1159/000057884
Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis
P. V. D. van de Kerkhof (2002)
10.1046/j.1365-2249.2003.02225.x
Pimecrolimus does not affect the differentiation, maturation and function of human monocyte‐derived dendritic cells, in contrast to corticosteroids
F. Kalthoff (2003)
10.1155/1996/213596
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
D. Malatjalian (1996)
10.1046/j.1365-2133.2003.05153.x
Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines
N. Litjens (2003)
10.1046/j.1365-2133.2001.04355.x
A comparison of the effect of narrow‐band ultraviolet B in the treatment of psoriasis after salt‐water baths and after 8‐methoxypsoralen baths
W. Arnold (2001)
10.1111/j.1365-2133.2004.05986.x
Efficacy of once‐daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris
K. Kragballe (2004)
[Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study].
W. M. Nugteren-Huying (1990)
10.1016/J.JAAD.2006.05.027
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
K. Gordon (2006)
10.1016/J.JAAD.2006.12.003
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
M. Papoutsaki (2007)
10.1007/S001050050401
[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].
P. Altmeyer (1996)
10.1016/S0926-9959(97)00181-5
Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
F. Kokelj (1998)
10.1111/j.1346-8138.2007.00305.x
Efficacy and safety of preprandial versus postprandial administration of low‐dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris
H. Hashizume (2007)
10.1080/09546630310019346
Fumaric acid esters in the treatment of psoriasis: an Italian experience
I. Carboni (2004)
10.1016/S0011-393X(05)80413-8
A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris
Å. Svensson (1992)
10.1038/357692A0
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
S. J. O'Keefe (1992)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1111/j.1365-2133.1994.tb02901.x
Methotrexate revisited: effects of long‐term treatment in psoriasis
R. J. Dooren-Greebe (1994)
10.7326/0003-4819-130-6-199903160-00004
Etanercept Therapy in Rheumatoid Arthritis
L. Moreland (1999)
10.2340/00015555-0511
The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
C. Zachariae (2008)
European Handbook of Dermatological Treatments. 2. Edition
A D Katsambas (2003)
10.1056/NEJMOA021359
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
V. M. Heydendael (2003)
10.1111/j.1365-2133.2007.07986.x
Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study
P. Gisondi (2007)
10.1111/J.1610-0387.2009.07312.X
Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab”
A. Nast (2010)
10.1016/S0140-6736(99)05246-0
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
R. Maini (1999)
10.1159/000210784
The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams.
S. de Mare (1988)
Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis
AF Finzi (1993)
Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate.
H. Meffert (1989)
10.1136/bmj.2.5808.296-a
Methotrexate hepatotoxicity in psoriasis.
T. Ryan (1972)
10.1016/S0140-6736(81)92137-1
ORAL 8-METHOXYPSORALEN PHOTOCHEMOTHERAPY OF PSORIASIS: The European PUVA Study: a Cooperative Study among 18 European Centres
T. Henseler (1981)
10.1111/j.1365-2133.2008.09023.x
Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis
K. Reich (2009)
10.1080/00015550310003791
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion.
U. Mrowietz (2003)
The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
C. Lee (2009)
10.1016/S0190-9622(98)70323-8
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
M. Lebwohl (1998)
10.1046/j.1365-2133.2002.04967.x
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double‐blind, vehicle‐controlled clinical trial
L. Guenther (2002)
10.1177/039463200702000324
Re-Induction as a Possible Alternative Modality of Dose Escalation of Infliximab: A Prospective Evaluation in a Small Series of Psoriatic Patients
N. Cassano (2007)
10.1111/j.1346-8138.2009.00622.x
Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open‐label study
E. Koç (2009)
10.1046/j.1529-8019.2003.01622.x
Balneotherapy in dermatology
H. Matz (2003)
Psoriasis -auf einen Blick. 1. Edition
E Christophers (2002)
10.1080/09546630801955358
Good clinical response to anti‐psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T‐cell subsets: A pilot study
R. G. van Lingen (2008)
10.1111/j.1365-2133.2008.08771.x
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension
P. V. D. van de Kerkhof (2008)
10.1046/j.1365-2133.1998.02554.x
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
Mrowietz (1998)
10.1046/j.1365-4362.2002.01431.x
A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
M. Lebwohl (2002)
An open, parallel groups, study of the importance of thoroughness of application in the treatment of psoriasis with a dithranol cream (Micanol).
N. Mørk (1992)
10.1111/j.1365-2133.2005.06688.x
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
K. Papp (2005)
Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis.
C. Orfanos (1979)
Handbook of Psoriasis. 2. Edition. Blackwell
C Camisa (2004)
10.1001/archdermatol.2009.5
Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
R. Mittal (2009)
10.1111/j.1365-2230.2008.02932.x
A randomized controlled trial to evaluate short‐term treatment with eosin vs. topical steroids in psoriasis
S. Tabolli (2009)
10.1111/j.1365-2133.1995.tb02670.x
A comparison of twice‐weekly MPD‐PUVA and three times‐weekly skin typing‐PUVA regimens for the treatment of psoriasis
D. Buckley (1995)
10.1111/j.1468-3083.2006.01565.x
Adherence to treatment in patients with psoriasis
H. Richards (2006)
10.1111/j.1365-2133.1992.tb00126.x
A multicentre, parallel‐group comparison of calcipotriol ointment and short‐contact dithranol therapy in chronic plaque psoriasis
J. Berth-Jones (1992)
10.1159/000232302
Impact of comorbidities on the management of psoriasis.
S. Gerdes (2009)
10.1111/j.1610-0387.2009.07120.x
Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis – A retrospective study (FUTURE)
K. Reich (2009)
10.1007/s00403-010-1080-1
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz (2010)
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
J. Decroix (2004)
10.1001/ARCHDERM.1980.01640280049016
Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals.
J. Robinson (1980)
10.1046/j.1365-2133.1999.02974.x
A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
Grassberger (1999)
10.1046/j.1365-2133.2002.04698.x
Combining lesional short‐contact dithranol therapy of psoriasis with a potent topical corticosteroid
O. Swinkels (2002)
10.1111/j.1468-3083.2007.02328.x
Topical 8‐methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque‐type psoriasis
P. Asawanonda (2008)
10.1200/JCO.1996.14.10.2769
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.
G. Rustin (1996)
10.1016/S0190-9622(99)80057-7
Patients with psoriasis and their compliance with medication.
H. Richards (1999)
10.1056/NEJM199101313240501
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.
C. Ellis (1991)
10.1001/ARCHDERM.139.3.325
Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.
T. Markham (2003)
Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis -A multicentre, randomized, double-blinded study
T Y Chuang (1991)
Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study
D Thaci (2002)
10.1159/000063148
Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris
H. Gollnick (2002)
10.1007/s00228-007-0442-x
The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis
J. Chládek (2007)
10.1080/09546630305545
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy
J. M. Camarasa (2003)
10.1159/000247323
Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis.
J. Shupack (1993)
Sequential treatment of psoriasis with infliximab followed by cyclosporin. Preliminary results of an open-label prospective study
G A Vena (2006)
10.1159/000018457
The Efficacy, Safety and Tolerance of Calcitriol 3 μg/g Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol
P. E. Hutchinson (2000)
A randomized trial of etanercept as monotherapy for psoriasis
T. Rindflesch (2005)
10.1046/j.1365-2133.1999.02927.x
Tacrolimus ointment improves psoriasis in a microplaque assay
Remitz (1999)
10.2340/00015555-0770
Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.
M. Augustin (2010)
10.1111/j.1468-3083.2007.02264.x
A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment
M. Hroch (2008)
Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
M. Jarratt (2006)
10.1159/000091250
Short Contact Therapy with Tazarotene in Psoriasis Vulgaris
S. Veraldi (2006)
10.1111/j.1365-4632.2007.03278.x
The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea
M. Harari (2007)
10.1067/MJD.2001.112400
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
V. Ho (2001)
10.1016/S0140-6736(00)04954-0
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U. Chaudhari (2001)
Gesundheitsberichterstattung des
H Traupe (2002)
10.1016/S0093-3619(08)79119-6
Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study
B. Thiers (2009)
10.1111/j.1468-3083.2007.02226.x
Intermittent vs. continuous 1‐year cyclosporin use in chronic plaque psoriasis
G. Chaidemenos (2007)
10.1136/oem.29.2.188
Scrotal cancer in the north-west of England, 1962-68
W. R. Lee (1972)
10.1034/j.1600-0781.2000.160502.x
Comparison of phototherapy two times and four times a week with low doses of narrow‐band ultraviolet B in Asian patients with psoriasis
V. Leenutaphong (2000)
10.1111/j.1365-2133.1992.tb00458.x
Inhibition of human monocyte functions by anthralin
U. Mrowietz (1992)
10.1016/S0140-6736(79)90820-1
COMPARISON OF PHOTOCHEMOTHERAPY AND DITHRANOL IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
S. Rogers (1979)
10.1111/j.0007-0963.2004.05739.x
Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities
P. Balasubramaniam (2004)
10.1016/S0002-9343(05)80060-9
Methotrexate and histologic hepatic abnormalities: a meta-analysis.
Q. Whiting-O'Keefe (1991)
Diffuse psoriasis plaque type and infliximab: our experience and review of literature
G Lemme (2007)
[On the treatment of psoriasis].
A. Vaag (1962)
10.2165/00128071-200607030-00004
Use of Calcipotriene Cream (Dovonex® Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex®)
S. White (2006)
10.1016/J.JAAD.2007.09.018
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
A. Nelson (2008)
A multicentre, parallelgroup comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis
J Berth-Jones
10.1016/0163-8343(89)90036-4
A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients.
M. Gupta (1989)
TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis
T Markham (2003)
10.1007/s00403-006-0707-8
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
U. Mrowietz (2006)
10.1016/S0190-9622(89)70138-9
Side-effect profile of acitretin therapy in psoriasis.
A. Gupta (1989)
10.1080/00015550510039817
0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study.
J. Ortonne (2006)
Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, doubleblind, placebo-controlled trial
A Salim (2006)
10.1046/j.1365-2133.2003.05115.x
Psoriasis patients who are homozygous for the HLA‐Cw*0602 allele have a 2·5‐fold increased risk of developing psoriasis compared with Cw6 heterozygotes
J. Gudjonsson (2003)
10.1046/J.1087-0024.2003.09102.X
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
R. Stern (2004)
10.1111/1523-1747.EP12274997
Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils.
J. Schröder (1985)
10.1016/S0190-9622(89)70085-2
Are topical corticosteroids useful in phototherapy for psoriasis?
J. S. Dover (1989)
10.1001/ARCHDERM.1984.01650450051017
Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis.
K. M. Diette (1984)
10.1684/EJD.2007.0234
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
K. Reich (2007)
10.1046/J.1523-1747.2003.12040.X
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
C. Paul (2003)
10.1177/039463200501800419
Non-Invasive Evaluation of Tacalcitol Plus Puva versus Tacalcitol Plus UVB-NB in the Treatment of Psoriasis: “Right-Left Intra-Individual — Pre/Post Comparison Design”
V. Brazzelli (2005)
10.1111/1523-1747.EP12499901
Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
A. Gottlieb (1992)
10.1016/J.JAAD.2006.07.017
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
A. Menter (2007)
10.1016/J.JAAD.2006.09.002
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
A. Moore (2007)
10.1016/J.NUT.2006.05.011
Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B.
A. Serwin (2006)
10.1016/S0190-9622(99)70112-X
Psoriasis causes as much disability as other major medical diseases.
S. Rapp (1999)
10.1046/j.1365-2230.2001.00870.x
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
M. Ameen (2001)
10.1046/j.1365-2133.2000.04713.x
Topical preparations for the treatment of psoriasis: a systematic review
J. Mason (2002)
10.1111/j.1468-3083.2004.01054.x
Psoriasis of the glans penis in a child successfully treated with ElidelR (pimecrolimus) cream
B. Amichai (2004)
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
L. Moreland (1999)
10.1111/j.1610-0387.2008.06919.x
Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany
M. Augustin (2009)
10.1016/J.JAAD.2004.06.010
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Carin H. Gribetz (2004)
10.1067/MJD.2003.103
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
G. Weinstein (2003)
10.1002/j.1552-4604.1995.tb04131.x
Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis
Cheryl A. Elder (1995)
10.1007/S10227-002-0114-5
The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions
A. Gottlieb (2003)
Werfel T. Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis
G Schmid-Ott (2001)
10.1111/j.1365-2133.2009.09593.x
Epidemiology and comorbidity of psoriasis in children
M. Augustin (2010)
10.1067/MJD.2000.107940
Tazarotene plus UVB phototherapy in the treatment of psoriasis.
J. Koo (2000)
10.1111/j.1365-2133.1989.tb01402.x
Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A
E. Higgins (1989)
Comparison of mometasone fluroate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris
V Peharda (2000)
10.1055/S-0029-1214673
Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen Recommendations for Tuberculosis Screening Before Initiation of TNF-α-Inhibitor Treatment in Rheumatic Diseases
R. Diel (2009)
Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for JDDG
B Kirby (2011)
10.1046/j.1365-2133.2002.04622.x
A cognitive‐behavioural symptom management programme as an adjunct in psoriasis therapy
D. Fortune (2002)
10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
A. V. van Ede (2001)
10.1177/039463200902200214
Angiogenesis in Psoriatic Skin and its Modifications after Administration of Etanercept: Videocapillaroscopic, Histological and Immunohistochemical Evaluation
A. Campanati (2009)
10.1016/J.JAAD.2004.02.021
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
A. Gottlieb (2004)
The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.
P. V. D. van de Kerkhof (1998)
The treatment of psoriasis
Mali Jw (1975)
Expertise zu Wirksamkeit und Nutzen von Harnstoff in der Therapie chronischer Hautkrankheiten. Wissenschaftliches Gutachten im Auftrag der Deutschen Dermatologischen Gesellschaft
M Augustin (2004)
10.1007/s00403-006-0723-8
Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy
C. Andrýs (2006)
10.2340/00015555756569
Remission of ordinary psoriasis following a short clearance course of cyclosporin.
N. Levell (1995)
10.1111/j.1365-2133.1996.tb07608.x
Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis
A. Pérez (1996)
10.1111/J.1523-1747.2003.12605.X
Dimethylfumarate is a potent inducer of apoptosis in human T cells.
F. Treumer (2003)
10.1001/ARCHDERM.1983.01650270025011
Topical steroids and UV radiation in psoriasis.
J. Petrozzi (1983)
10.1067/MJD.2000.108319
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
M. Lebwohl (2000)
10.1111/j.1600-0536.1996.tb02199.x
Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations
M. Schiavi (1996)
10.2340/0001555577137141
Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
H. Meffert (1997)
10.1126/SCIENCE.1145697
Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
D. Mucida (2007)
10.1159/000252574
Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy.
A. Nyfors (1970)
10.1067/MJD.2002.120454
Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study.
S. Feldman (2002)
Global safety and efficacy of up to five years of etanercept (Enbrel) therapy
L Klareskog (2001)
10.1007/s00439-007-0397-0
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis
F. Capon (2007)
10.1159/000017504
Empfehlungen zur Erfassung von Lebensqualität in der Dermatologie
M. Augustin (2000)
10.1016/S0093-3619(09)79428-6
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
J. Weinberg (2010)
10.1080/09546630701646156
Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet®) versus calcipotriol (Daivonex®) in the treatment of psoriasis vulgaris: A randomized, multicentre, clinical trial
R. Saraceno (2007)
10.1111/j.1365-2133.1975.tb06498.x
A prospective study of the effects of weekly oral methotrexate on liver biopsy
A. Warin (1975)
10.1046/j.1365-2133.2000.03883.x
Acitretin is converted to etretinate only during concomitant alcohol intake
F. Grønhøj Larsen (2000)
Etanercept (Enbrel) monotherapy for more than 5 years in patients with DMARD-refrectory rheumatoid arthritis
L W Moreland (2002)
10.1111/j.1346-8138.2007.00275.x
Clinical usefulness and patient satisfaction for treatment with low‐dose cyclosporin administration in patients with moderate psoriasis vulgaris
M. Abe (2007)
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
A. Menter (2009)
10.1111/j.1365-2230.1978.tb01512.x
A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis
D. Vella Briffa (1978)
10.1111/J.1610-0387.2007.06172.X
Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris
A. Nast (2007)
10.1067/MJD.2002.120472
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
R. Schopf (2002)
Intralesional cyclosporin in psoriasis.
A. Powles (1989)
10.2340/00015555-0290
Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis.
G. M. Ezquerra (2007)
Stat-5 independent signaling pathway
(2008)
10.1111/j.1365-2133.1990.tb01481.x
Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis
P. Petzelbauer (1990)
10.1016/S0140-6736(08)60725-4
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
C. Leonardi (2008)
LTBI = Latent tuberculosis infection, TB = tuberculosis, TST = Tuberculin skin test, IGRA = Interferon-Gamma Release Assay
10.1001/ARCHDERM.1989.01670210056007
The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment.
M. Newman (1989)
10.1177/039463200902200125
A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project
G. Vena (2009)
10.1111/j.1365-2133.2005.06827.x
Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis
S. Taibjee (2005)
10.1089/ACM.2007.7099
A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis.
T. Brockow (2007)
10.1080/00015550310022916
Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis.
E. Snellman (2004)
10.1111/1523-1747.EP12319272
Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial.
A. Fleischer (1997)
10.1111/j.1365-2133.2007.08236.x
Impact of adalimumab treatment on health‐related quality of life and other patient‐reported outcomes: results from a 16‐week randomized controlled trial in patients with moderate to severe plaque psoriasis
D. Revicki (2008)
A comperative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris
A R Svensson (1992)
10.1111/j.1524-4725.2008.34386.x
A Comparative Study on the Efficacy of Treatment with 585 nm Pulsed Dye Laser and Ultraviolet B‐TL01 in Plaque Type Psoriasis
J. D. de Leeuw (2009)
Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, doubleblind, placebo-controlled clinical trial
R Mittal (2009)
10.1159/000057974
Atopic Eczema Prevention Program in Childhood and Adolescence – a Model Project of the GermanGovernment
G. Schmid‐Ott (2000)
10.1055/S-2004-813336
Systematik der Nutzenbewertung von Arzneimitteln
R. Rychlik (2004)
Translating psoriasis treatment guidelines into clinical practice -the need for educational interventions and strategies for broad References S77 dissemination
A Nast (2008)
10.1001/ARCHDERM.1979.04010090024017
Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate.
C. Hanke (1979)
10.1016/S0190-9622(03)00792-8
Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis.
M. Grundmann-Kollmann (2004)
10.1001/ARCHDERM.1985.01660100077019
Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis.
R. Moy (1985)
Tuberculosis reports with etanercept (Enbrel) therapy
J Holman (2002)
10.1046/j.1365-2133.2003.05433.x
Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
J. Hoefnagel (2003)
10.1111/j.1468-3083.1998.tb00948.x
Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis
J. Austad (1998)
10.1046/J.1365-2133.2001.04376.X
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
S. Reitamo (2001)
10.1517/14728222.11.5.601
IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases
R. Sabat (2007)
10.1111/j.1365-2133.2006.07393.x
A comparison of twice‐daily calcipotriol ointment with once‐daily short‐contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day‐care setting
P. V. D. van de Kerkhof (2006)
10.1055/S-2008-1063827
[Cyclosporins in dermatology].
U. Mrowietz (1991)
Systemic therapy of psoriasis using methotrexate.
K. Smith (2000)
10.1046/j.1365-2133.1996.d01-1035.x
Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease
G. J. Nevitt (1996)
10.1111/j.1365-2133.2006.07316.x
Infliximab for severe, treatment‐resistant psoriasis: a prospective, open‐label study
C. Smith (2006)
10.1046/j.1365-2133.1998.02030.x
The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis
Van De Kerkhof (1998)
10.1002/9780470750704
Handbook of Psoriasis
C. Camisa (1998)
10.1111/j.1346-8138.2006.00022.x
Daily versus intermittent application of high‐concentration tacalcitol ointment in combination with low‐dose cyclosporin for psoriasis vulgaris
M. Abe (2006)
10.1111/j.1600-0560.2006.00571.x
Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis
E. Lago (2007)
10.1097/00000441-195102000-00009
THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITY: II. Effect of Aminopterin in Rheumatoid Arthritis and Psoriasis
R. Gubner (1951)
10.1016/S0733-8635(18)30045-7
Tars and anthralins.
A. Silverman (1995)
10.1111/J.1600-0536.1994.TB01965.X
Intolerance and contact allergy to tar and dithranol in psoriasis
A. Burden (1994)
10.1001/ARCHDERM.134.9.1101
Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.
I. Zonneveld (1998)
10.1159/000065971
Calcipotriol Plus Short-Contact Dithranol: A Novel Topical Combination Therapy for Chronic Plaque Psoriasis
A. Monastirli (2002)
10.1046/j.1365-2133.1998.02319.x
A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
Koo (1998)
10.1111/j.1346-8138.2002.tb00321.x
A Novel Liposomal Formulation of Dithranol for Psoriasis: Preliminary Results
R. Agarwal (2002)
10.1016/0190-9622(91)70089-K
Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone.
N. Lowe (1991)
10.1111/1523-1747.EP12461062
Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry.
W. Weston (1988)
10.1111/j.1365-2133.1992.tb00460.x
Bath‐water compared with oral delivery of 8‐methoxypsoralen PUVA therapy for chronic plaque psoriasis
P. C. Llins (1992)
Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment
H Zachariae (1980)
10.1016/S0149-2918(00)83065-9
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
L. Guenther (2000)
10.1016/0190-9622(93)70069-6
Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis.
P. Duhra (1993)
10.1016/0092-8674(91)90124-H
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
J. Liu (1991)
10.1016/S0190-9622(94)70121-0
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.
P. Altmeyer (1994)
10.1001/ARCHDERM.1982.01650170033018
The role of tar in Goeckerman therapy.
D. Belsito (1982)
10.1111/j.1529-8019.2009.01250.x
Focused UV‐B narrowband microphototherapy (Biopsorin®). A new treatment for plaque psoriasis
T. Lotti (2009)
10.1111/j.1365-2133.2007.08284.x
Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial
I. Flytström (2008)
Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVBsparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group
C A Ramsay (2000)
10.1159/000018309
Calcipotriol Cream Combined with Twice Weekly Broad-Band UVB Phototherapy: A Safe, Effective and UVB-Sparing Antipsoriatric Combination Treatment
C. Ramsay (2000)
10.1016/j.clindermatol.2007.10.024
Economic considerations in psoriasis management.
M. Radtke (2008)
10.1001/ARCHDERM.143.5.586
Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial.
R. Schiener (2007)
10.1080/09546630701418747
A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis
H. Yoon (2007)
10.1111/j.1365-2133.2007.08315.x
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
Jean-Hilaire Saurat (2008)
10.1016/S0190-9622(89)70154-7
Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
A. Finzi (1989)
10.1016/S0190-9622(84)70188-5
Role of ultraviolet A in phototherapy for psoriasis.
K. M. Diette (1984)
10.1111/j.1365-2133.2008.08728.x
Review and expert opinion on prevention and treatment of infliximab‐related infusion reactions
L. Lecluse (2008)
10.1080/00015550252948194
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
W. S. Douglas (2002)
10.1111/j.1365-2230.2008.02718.x
Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V
J. Kaur (2008)
10.1016/S0190-9622(08)80228-9
Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment.
D. N. Kolbach (1992)
10.1001/ARCHDERM.140.4.408
Objective assessment of compliance with psoriasis treatment.
S. Zaghloul (2004)
10.1001/JAMA.296.14.1735
Risk of myocardial infarction in patients with psoriasis.
J. Gelfand (2006)
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Y. Poulin (1999)
10.1159/000012336
A Pilot Study of Hypnosis in the Treatment of Patients with Psoriasis
F. Tausk (1999)
10.2340/00015555-0529
A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis.
M. Ozdemir (2008)
10.1111/j.1365-2133.2009.09505.x
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
C. Smith (2009)
10.1111/j.1365-2133.2005.06306.x
Safety and efficacy study on etanercept in patients with plaque psoriasis
A. Costanzo (2005)
10.1111/j.1468-3083.2006.01913.x
An investigator‐masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 µg/g ointment vs. calcipotriol 50 µg/g ointment in subjects with mild to moderate chronic plaque‐type psoriasis
X. Zhu (2007)
Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris
P Altmeyer
10.1111/j.1365-2133.1995.tb02754.x
Sequential liver biopsies during long‐term methotrexate treatment for psoriasis: a reappraisal
M. Boffa (1995)
10.1016/S0140-6736(05)67763-X
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
Stephen K. Tyring (2006)
10.1046/J.1523-1747.2001.01159.X
Inhibition of dendritic cell differentiation by fumaric acid esters.
K. Zhu (2001)
10.1086/511051
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
M. Cargill (2007)
10.1097/00006842-199809000-00020
Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients With Moderate to Severe Psoriasis Undergoing Photo Therapy (UVB) and Photochemotherapy (PUVA)
J. Kabat-Zinn (1998)
10.1056/NEJMOA030409
Etanercept as monotherapy in patients with psoriasis.
C. Leonardi (2003)
10.1080/09546630410017275
A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab
N. Scheinfeld (2004)
Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis
M Lebwohl (2005)
10.1111/j.1365-2133.1992.tb00460.x
Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
P. Collins (1992)
10.1016/S0140-6736(05)67566-6
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K. Reich (2005)
10.1111/j.1600-0781.2007.00294.x
Twice‐ vs. thrice‐weekly MPD PUVA in psoriasis: a randomized‐controlled efficacy study
M. Valbuena (2007)
10.1007/s00403-007-0744-y
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)
A. Nast (2007)
Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects.
A. Takeuchi (1998)
A new treatment of ichthyosis and other hyperkeratotic conditions.
G. Swanbeck (1968)
10.1016/S0140-6736(01)06179-7
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study
I. Marcil (2001)
10.1111/j.1600-0846.2008.00336.x
Microcirculatory modifications of psoriatic lesions during topical therapy
P. Rosina (2009)
10.1023/B:EJEP.0000020447.59150.f9
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients
L. Mallbris (2004)
10.1182/BLOOD-2007-06-096438
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.
Kevin M. Elias (2008)
10.1080/13547500701600597
Soluble tumour necrosis factor-α receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis
A. Serwin (2007)
10.1007/s00403-008-0887-5
The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis
T. Ohtsuka (2008)
10.1016/S0190-9622(89)70071-2
Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis.
C. Nieboer (1989)
10.1111/j.1365-2133.2006.07562.x
Psoriasis: a possible risk factor for development of coronary artery calcification
R. Ludwig (2007)
10.1016/J.JAAD.2006.05.024
Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis.
Rujirat Vongthongsri (2006)
Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis.
P. Thune (1992)
10.1159/000249273
Irritant potential of dithranol.
U. F. Haustein (1986)
The chemestry, pharmacology abd use of tar in treatment of psoriasis
C Grupper (1971)
10.1111/j.1365-2230.1986.tb00457.x
Salicyclic acid gel for scalp psoriasis
S. Going (1986)
10.1001/ARCHDERM.138.9.1221
The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review.
J. de Korte (2002)
10.1016/S0149-2918(97)80094-X
Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
R. S. Medansky (1997)
Ciclosporin in der Dermatologie
U. Mrowietz (2003)
10.1001/ARCHDERM.1992.01680160143028
The effect of flash lamp-pulsed dye laser on psoriasis.
S. M. Hacker (1992)
10.1046/j.1365-2230.2000.00589.x
A comparison of bathwater and oral delivery of 8‐methoxypsoralen in PUVA therapy for plaque psoriasis
Cooper (2000)
10.3109/09546639809160546
A comparison of the efficacy and safety of the combination mometasone furoate 0.1 %/salicylic acid 5% ointment with each of its components in psoriasis
H. Katz (1998)
10.1016/S0190-9622(88)70086-9
Acitretin improves psoriasis in a dose-dependent fashion.
M. T. Goldfarb (1988)
10.1159/000066440
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris
R. Kaufmann (2002)
10.1159/000029819
Dithranol Embedded in Crystalline Monoglycerides Combined with Phototherapy (UVB): A New Approach in the Treatment of Psoriasis
M. Gerritsen (1998)
10.1111/j.1365-2133.2008.08564.x
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24‐week, randomized, controlled, investigator‐blinded pilot trial
P. Gisondi (2008)
10.1080/09546630510041060
Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque‐type psoriasis
N. Lowe (2005)
Benefits and adverse drug
A. Nyfors (1994)
10.1006/BBRC.1997.6570
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.
M. Vandermeeren (1997)
10.1016/S0190-9622(98)70214-2
Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
P. Calzavara-Pinton (1998)
10.1001/ARCHDERM.143.12.1493
The risk of mortality in patients with psoriasis: results from a population-based study.
J. Gelfand (2007)
10.1111/j.1365-2133.2006.07675.x
A classification of psoriasis vulgaris according to phenotype
C. Griffiths (2007)
10.1016/S0190-9622(96)90025-0
Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate
E. Sherertz (1996)
10.1111/1524-4725.2006.32044
Comparison of the Effects of Pulsed Dye Laser, Pulsed Dye Laser + Salicylic Acid, and Clobetasole Propionate + Salicylic Acid on Psoriatic Plaques
T. Ilknur (2006)
10.1111/j.1365-2133.2008.08618.x
Relevance of compartmentalization of T‐cell subsets for clinical improvement in psoriasis: effect of immune‐targeted antipsoriatic therapies
R. G. van Lingen (2008)
10.1007/S10227-001-0031-Z
A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis
L. Green (2002)
10.1111/j.1365-2133.1995.tb06924.x
Laser treatment of psoriasis
G. Katugampola (1995)
10.1016/S0190-9622(82)70005-2
Combined methotrexate-PUVA therapy in the treatment of psoriasis.
W. Morison (1982)
10.1111/j.1699-0463.1976.tb00098.x
Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study.
A. Nyfors (1976)
10.1016/J.JAAD.2007.07.042
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
P. Rich (2008)
10.1111/j.1365-4362.1988.tb02429.x
Acitretin (Ro 10‐1670) in the Treatment of Severe Psoriasis
A. Ledo (1988)
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
K. Kragballe (1989)
Tuberculosis reports with etanercept (Enbrel) therapy. Ann Dis Rheum
J Holman (2002)
10.1097/00000441-196711000-00059
Therapie Der Hautkrankheiten
C. Orfanos (1995)
10.1067/MJD.2003.130
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
K. Papp (2003)
[Influence of cyclosporin A on psoriasis].
W. Müller (1979)
10.1111/j.1346-8138.1988.tb03652.x
Combination of Photochemotherapy (PUVA) and Ultraviolet B (UVB) in the Treatment of Psoriasis Vulgaris
Y. Park (1988)
Cost Effectiveness of Biologic Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis
K Schmitt-Rau
10.1007/s00403-006-0703-z
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
Dorothea M. Sommer (2006)
[Photochemotherapy by 8-methoxypsoralen and UVA in psoriasis vulgaris--clinical experiences in 5 dermatological departments of GDR (author's transl)].
J. Barth (1978)
Management of guttate and generalized psoriasis vulgaris: prospective randomized study.
N. G. Caca-Biljanovska (2002)
10.1111/j.1365-2133.1994.tb02935.x
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis
C. Laburte (1994)
10.1016/J.MOLMED.2004.11.003
Dimethylfumarate for psoriasis: more than a dietary curiosity.
U. Mrowietz (2005)
10.1002/9780470987421
Textbook of Psoriasis
P. Kerkhof (1986)
10.1111/1523-1747.EP12506317
The effect of topical fluocinonide ointment on phototherapy of psoriasis.
M. Levine (1982)
[Acute toxic polyneuropathy following short-time hydroxyquinoline administration].
W. Müller (1979)
10.1159/000029933
Dithranol in a Cream Preparation: Disperse or Dissolve?
M. Prins (2000)
10.1056/NEJM197412052912301
Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.
J. Parrish (1974)
10.1111/j.1468-3083.2009.03537.x
Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population‐based sample
J. Schmitt (2010)
10.4049/jimmunol.167.9.4974
1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1
A. Boonstra (2001)
10.1177/205873920601900123
Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
N. Cassano (2006)
10.1016/S0149-2918(98)80091-X
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
J. Koo (1998)
An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
K. Beutner (2006)
10.1097/00007611-197811000-00009
Treatment of Psoriasis With 8‐Methoxypsoralen and Sunlight
D. Robertson (1978)
10.1159/000119415
Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany
M. Augustin (2008)
10.1016/S0190-9622(99)70008-3
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis.
P. Gordon (1999)
10.1016/S0190-9622(88)70198-X
Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
H. Gollnick (1988)
10.1016/S0190-9622(99)70362-2
Acitretin in combination with UVB or PUVA.
M. Lebwohl (1999)
10.1111/j.1468-3083.2006.01387.x
A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis
A. Pacifico (2006)
10.1016/J.JAAD.2005.09.012
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris.
M. Magliocco (2006)
10.1159/000246849
Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.
P. Calzavara-Pinton (1994)
10.1001/ARCHDERM.1971.04000130035004
Methotrexate for psoriasis. A new therapeutic schedule.
G. Weinstein (1971)
A randomized double-blind comparison of PUVAetretinate and PUVA-placebo in the treatment of chronic plaque psoriasis
S Parker
Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques.
G. Martín Ezquerra (2006)
10.1111/j.1365-2133.1984.tb07470.x
A randomized double‐blind comparison of PUVA‐etretinate and PUVA‐placebo in the treatment of chronic plaque psoriasis
S. Parker (1984)
Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis-a retrospective study (FU-TURE)
K Reich (2009)
10.1067/MJD.2003.417
The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
T. S. Housman (2003)
10.1046/j.1365-2133.1999.02976.x
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis
Clark (1999)
10.1016/S0190-9622(98)70508-0
Methotrexate in psoriasis: consensus conference.
H. Roenigk (1998)
10.1067/MAI.2001.111850
Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis.
G. Schmid-Ott (2001)
10.1111/j.1365-2133.2006.07289.x
Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double‐blind, placebo‐controlled trial
A. Salim (2006)
10.1080/09546630310021947
A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser
T. S. Housman (2004)
10.2340/0001555575393396
Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate.
R. V. van Dooren-Greebe (1995)
Systemic therapy of psoriasis using methotrexate.
Smith Kc (2000)
10.1002/EJI.1830260916
Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate
R. D. de Jong (1996)
Nonlaser UVB-targeted phototherapy treatment of psoriasis.
M. Kaur (2006)
10.1001/ARCHDERM.1997.03890480034005
Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B.
T. Coven (1997)
Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography.
K. Mustakallio (1979)
10.1016/0167-5699(93)90061-O
The mechanisms of action of cyclosporin A in the treatment of psoriasis.
R. Wong (1993)
10.1007/978-3-642-86183-3
Dermatologie und Venerologie
O. Braun-Falco (1969)
[Results of cyclosporin treatment of severe, chronic psoriasis vulgaris].
R. Engst (1989)
10.1111/j.1468-3083.2008.02841.x
Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry
A. Nast (2008)
25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells
A Boonstra (2001)
A comparison between Antraderm stick (0.5% and 1%) and dithranol paste (0.125% and 0.25%) in the treatment of JDDG
G Agrup (2011)
10.1159/000106791
Cost-Effectiveness Model of Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Germany
M. Augustin (2007)
Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study
J Ring (2001)
Fachinformation Wyeth. aktuelle Version
10.1111/j.1529-8019.2008.00227.x
Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis
M. Bongiorno (2008)
10.1046/j.1365-2133.1998.02400.x
The antipsoriatic agent dimethylfumarate immunomodulates T‐cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network
Ockenfels (1998)
10.1080/09546630601121086
Etanercept and efalizumab treatment for high‐need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice
M. A. M. Berends (2007)
10.1007/s10875-008-9233-0
Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial
M. Caproni (2008)
A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis.
H. Fabry (1983)
Management of psoriasis: A clinical evaluation of the dermatological patch, Actidermregistered trade mark, over a topical steroid
F Bagatell (1988)
10.1159/000080854
Efficacy of Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol for the Treatment of Psoriasis vulgaris: A Randomised, Double-Blind Trial
J. Ortonne (2004)
10.1177/039463200401700321
Association of Cyclosporine and 311 nM UVB in the Treatment of Moderate to Severe Forms of Psoriasis: A New Strategic Approach
C. Franchi (2004)
10.1111/j.1365-2133.2004.06070.x
Biological therapies in the systemic management of psoriasis: International Consensus Conference
W. Sterry (2004)
10.1001/ARCHDERM.139.4.436
Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
Christopher S Carlin (2003)
10.1159/000093852
Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris
S. Goldinger (2006)
10.1016/J.JAAD.2004.09.012
Remission and time of resolution of nail psoriasis during infliximab therapy.
L. Bianchi (2005)
10.1111/j.1529-8019.2008.00200.x
Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy
A. Peroni (2008)
10.1016/S0190-9622(96)80148-4
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994.
M. Menter (1996)
10.1016/0190-9622(91)70091-F
A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.
H. Murray (1991)
Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
M. Berg (1994)
10.1006/PHRS.1996.0069
Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea.
A. Kushelevsky (1996)
10.1046/j.1365-4362.2001.01167.x
Investigator‐masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis
J. Koo (2001)



This paper is referenced by
10.1007/978-3-642-24767-5_2
Schwere Psoriasis – immer Biologics?*
M. Goebeler (2013)
10.1002/14651858.CD010497.pub2
Oral fumaric acid esters for psoriasis.
A. Atwan (2015)
10.1007/s00105-014-3569-6
Photosensibilisierung durch Methotrexat
K. Hoffmann (2014)
Risk of cancer after coal tar treatment
J.H.J. Roelofzen (2013)
Combination of Qinzhu Liangxue Decoction and acitretin on the treatment of psoriasis vulgaris : a randomized controlled trail
Hongyu Sha (2016)
Evaluation of lipid profile for psoriatic patients treated by cyclosporine and biological treatment
N. Hamad (2017)
10.2147/PPA.S29285
It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis
N. Umar (2012)
10.3109/09546634.2012.658015
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)
R. Strohal (2013)
10.1111/bjd.15005
Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis
J. Reek (2017)
10.3109/09546634.2014.946882
Saudi practical guidelines on biologic treatment of psoriasis
I. Hamadah (2015)
10.1111/jdv.15962
Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study
D. Thąci (2019)
10.1159/000455042
Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry
Pierre Jungo (2016)
10.1111/j.1610-0387.2012.07926.x
Methotrexate therapy in dermatology
K. Reich (2012)
10.1007/s00393-017-0340-2
Differenzialdiagnostisches Spektrum der Psoriasis versus Psoriasisarthritis an Haut und Gelenken
Sonka Gerdes (2017)
10.20344/AMP.12
Recommendations for High-Quality Use of Biologic Therapies in Adults with Plaque Psoriasis
G. Pinto (2011)
10.1007/s15014-015-0410-3
Altersabhängige therapeutische Besonderheiten
med. Marc Pleimes (2015)
10.1111/ddg.14087
Chronic kidney disease in psoriasis: a cohort study
A. Conti (2020)
10.1111/ddg.13050
Pathophysiological basis of systemic treatments in psoriasis
S. Volc (2016)
Konvenční systémová léčba chronické plakové psoriázy v éře biologik
Alena Machovcová Mba (2013)
A protocol of systematic review and meta-analysis
Jing Li (2020)
Effect of Acitretin on Serum Biomarkers Levels in Patients with Psoriasis
A. Alobaidi (2016)
10.1159/000452740
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT
J. Maul (2016)
10.1111/ddg.12912
S1‐Guidelines on UV phototherapy and photochemotherapy
T. Herzinger (2016)
10.1155/2015/792968
Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression
A. Schwandt (2015)
10.1007/s00105-012-2526-5
CD30-positives anaplastisch großzelliges T-Zell-Lymphom unter immunsuppressiver Therapie einer Pityriasis rubra pilaris mit Ustekinumab
D. Humme (2012)
German S3-guidelines on the treatment of psoriasis vulgaris (short version) A. NastW. H. BoehnckeU. MrowietzH. M. OckenfelsS. PhilippK. ReichT. Rosenbach • A. SammainM. SchlaegerM. SebastianW. SterryV. StreitM. AugustinR. ErdmannJ. Klaus •
J. KozaS (2012)
10.3109/09546634.2012.742176
Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group
Maria Lorna F Frez (2014)
10.12659/MSM.919392
Baicalin Inhibits Cell Proliferation and Inflammatory Cytokines Induced by Tumor Necrosis Factor α (TNF-α) in Human Immortalized Keratinocytes (HaCaT) Human Keratinocytes by Inhibiting the STAT3/Nuclear Factor kappa B (NF-κB) Signaling Pathway
X. Wu (2020)
10.1111/jdv.12981
Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics
P. Sator (2015)
10.1111/ddg.13810
Topische Therapie bei Psoriasis vulgaris – ein Behandlungspfad
A. Körber (2019)
Primjena suvremenih topikalnih pripravaka u liječenju psorijaze
I. Petric (2017)
10.1007/s00105-016-3827-x
Magistralrezepturen zur topischen Therapie des Pruritus
P. D. P. Staubach (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar